These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 16862656)

  • 1. Reader comments on complementary and alternative medicine articles.
    Lyttle T
    Oncol Nurs Forum; 2006 Jul; 33(4):684; author reply 684. PubMed ID: 16862656
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents.
    Dev Biol Stand; 1998; 93():133-4. PubMed ID: 9737391
    [No Abstract]   [Full Text] [Related]  

  • 3. Examination of the biological safety of a drug derived from mammalian organs.
    Hübner GE; Koch RC; Sprenger KB; Stadler PJ; Gölker CF
    Arzneimittelforschung; 1996 Jun; 46(6):657-61. PubMed ID: 8767361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Industry self-regulation in the manufacture of dietary supplements and botanical medicines.
    Goldman EL
    Clin Obstet Gynecol; 2001 Dec; 44(4):789-800. PubMed ID: 11600860
    [No Abstract]   [Full Text] [Related]  

  • 5. Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):113-21. PubMed ID: 9359933
    [No Abstract]   [Full Text] [Related]  

  • 6. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):155-8. PubMed ID: 1389111
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
    Rohwer RG
    Dev Biol Stand; 1996; 88():247-56. PubMed ID: 9119146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmissible spongiform encephalopathies and the safety of naturally-derived biologicals.
    Di Martino A
    Biologicals; 1993 Mar; 21(1):61-6. PubMed ID: 8217119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of bovine spongiform encephalopathy.
    Kimberlin RH
    Dev Biol Stand; 1991; 75():75-82. PubMed ID: 1838995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of natural products on developing new anti-cancer agents.
    Cragg GM; Grothaus PG; Newman DJ
    Chem Rev; 2009 Jul; 109(7):3012-43. PubMed ID: 19422222
    [No Abstract]   [Full Text] [Related]  

  • 13. [BSE and heparin and gelatin preparations].
    Laubenthal H
    Anaesthesist; 1997 Mar; 46(3):253-4. PubMed ID: 9163271
    [No Abstract]   [Full Text] [Related]  

  • 14. [BSE risk with gelatin ?].
    Med Monatsschr Pharm; 1995 Jul; 18(7):199-200. PubMed ID: 7651275
    [No Abstract]   [Full Text] [Related]  

  • 15. Trials of protecting Poland from acquiring bovine spongiform encephalopathy.
    Kita J; Maciołek H
    Arch Immunol Ther Exp (Warsz); 1998; 46(2):65-8. PubMed ID: 9613702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural products, both small and large, and a focus on cancer treatment.
    McAlpine J; Romano A; Ecker D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):186-8. PubMed ID: 19333863
    [No Abstract]   [Full Text] [Related]  

  • 17. Mad colloid disease?
    Bedforth NM; Hardman JG
    Anaesthesia; 1997 Apr; 52(4):389-90. PubMed ID: 9135205
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioactive natural products from endophytes: a review.
    Guo B; Wang Y; Sun X; Tang K
    Prikl Biokhim Mikrobiol; 2008; 44(2):153-8. PubMed ID: 18669256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine contamination of biological products.
    Wadhwa M; Thorpe R
    Biologicals; 1997 Sep; 25(3):307-18. PubMed ID: 9324999
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of natural products in modern drug development.
    Dev S
    Indian J Exp Biol; 2010 Mar; 48(3):191-8. PubMed ID: 21046971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.